Resistin-like molecule alpha1 (Fizz1) recruits lung dendritic cells without causing pulmonary fibrosis by Satish K Madala et al.
Madala et al. Respiratory Research 2012, 13:51
http://respiratory-research.com/content/13/1/51RESEARCH Open AccessResistin-like molecule alpha1 (Fizz1) recruits lung
dendritic cells without causing pulmonary fibrosis
Satish K Madala1*, Ramakrishna Edukulla1, Katy R Davis2, Stephanie Schmidt1, Cynthia Davidson1,
Joseph A Kitzmiller2, William D Hardie1 and Thomas R Korfhagen2Abstract
Background: Resistin-like molecule alpha or found in inflammatory zone protein (Fizz1) is increased in pulmonary
epithelial cells and also in limited amounts by other lung cells during various lung injuries and fibrosis. However,
the direct role of Fizz1 produced in the pulmonary epithelium has not been determined.
Methods: Fizz1 Transgenic mice (CCSP/Fizz1) were generated that overexpress Fizz1 in the lung epithelium under
the control of a doxycycline (Dox) inducible lung epithelial cell specific promoter Scgb1a1 (Clara cell secretory
protein, CCSP). Histology and FACS analysis of lung cells were used to identify the direct effects of Fizz1 in the
transgenic mice (Dox treated) when compared with control (CCSP/-) mice. Intratracheal bleomycin sulfate or silica
in saline and saline alone were used to study the role of Fizz1 during bleomycin- and silica-induced pulmonary
fibrosis in CCSP/Fizz1 and CCSP/- mice. Weight change, pulmonary inflammation, and fibrosis were assessed
10 days post bleomycin or 28 days post silica challenge.
Results: When CCSP/Fizz1 mice were fed Dox food, elevated Fizz1 protein was detected in lung homogenates by
western blot. Lungs of mice in which Fizz1 was induced in the epithelium contained increased lung cells staining
for CD11c and F4/80 by FACS analysis consistent with increased dendritic cells however, no changes were observed
in the percentage of interstitial macrophages compared to CCSP/- controls. No significant changes were found in
the lung histology of CCSP/Fizz1 mice after up to 8 weeks of overexpression compared to CCSP/- controls.
Overexpression of Fizz1 prior to challenge or following challenge with bleomycin or silica did not significantly alter
airway inflammation or fibrosis compared to control mice.
Conclusions: The current study demonstrates that epithelial cell derived Fizz1 is sufficient to increase the bone-
marrow derived dendritic cells in the lungs, but it is not sufficient to cause lung fibrosis or alter chemical or
particle-induced fibrosis.
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Lung remodeling in the distal airspace and parenchyma
is characterized by excessive extracellular matrix depos-
ition and accumulation of apoptosis-resistant and colla-
gen producing myofibroblasts. Currently there are no
effective therapeutic treatments available for pulmonary
fibrosis highlighting the importance of identifying target-
able cells, fibrogenic pathways and molecules to design
therapeutic approaches and to use as biomarkers of* Correspondence: satish.madala@cchmc.org
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reproduction in any medium, provided the ordisease progression. Multiple rodent models have been
established that recapitulate mechanisms leading to pul-
monary fibrosis and identify cells, pathways and growth
factors mediating pulmonary fibrosis [1-6]. Resistin-like
molecules or found in inflammatory zone (FIZZ) are a
family of cysteine-rich secreted small proteins which
have been shown to play an important role in the cell
differentiation implicated in the pathophysiology of
chronic diseases including obesity, type 2 diabetes, hel-
minth infections and forms of pulmonary fibrosis [7-12].
The family consists of 4 members: Relm-α/Fizz1, Relm-β
/Fizz2, Resistin/Fizz3, and Relm-γ/Fizz4. In the lung,
Fizz1 is induced in environments with Th2-cytokineLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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IL13/IL4-driven STAT 6 activation. In hypoxic injury,
Fizz1 is induced independent of IL4 [8]. The expression
pattern of Fizz1 resembles resistin suggesting functional
overlap between mouse derived Fizz1 and human resis-
tin [13]. In vitro studies demonstrate that Fizz1 activates
type I collagen expression in fibroblasts via a notch1-
dependent pathway [10]. In addition, Fizz1 transforms
fibroblasts to collagen producing myofibroblasts and
induces anti-apoptotic responses in myofibroblasts con-
tributing to excess myofibroblast accumulation and pro-
duction of extracellular matrix proteins in the lung [10].
Previous studies provide conflicting evidence regarding
the in vivo involvement of Fizz1 in promoting forms of
pulmonary fibrosis [7-10,14]. Fizz1 overexpression using
adenoviral gene transfer or hypoxia increased the re-
cruitment of bone marrow derived cells (BMD) to the
lung and increased vascular remodeling with fibrotic
changes localized to pulmonary arteries [8,15]. In a
mouse model of hypoxia-induced pulmonary hyperten-
sion, the recruitment of BMD cells was associated with a
concomitant increase in Fizz1 levels in the lung. How-
ever, Fizz1 knockout mice challenged with the parasitic
eggs of S. mansoni eggs displayed heightened pulmonary
fibrosis associated with increases in CD4+ Th2 cell
derived IL-4 and IL-13 [7,9] suggesting that Fizz1 is a
negative regulator of pro-fibrotic Th2 cytokines induced
by parasitic infections.
Transforming growth factor-α (TGFα) is a ligand for
the epidermal growth factor receptor (EGFR) and trans-
genic mice conditionally expressing TGFα specifically in
the lung epithelium develop progressive fibrosis accom-
panied with cachexia, changes in lung mechanics and
secondary pulmonary hypertension [16,17]. Microarray
analysis of whole lung homogenates in the TGFα mice
demonstrates increases in Fizz1 transcripts following the
induction of the transgene [16]. Fizz1 was originally
reported to be induced primarily in lung epithelial cells
in Ova [18] and Aspergillus models [19] and in a hyp-
oxia model [8]. Fizz1 is also induced in macrophages in
asthma models and eosinophils in asthma and helminth
infection models [7,19]. More recently Fizz1 has been
reported in alternatively activated macrophages [20]. Re-
cent studies using Fizz1 reporter mice confirm that lung
epithelial cells are a major source for Fizz1 in the lung
[7]. As the direct role of Fizz1 in the pathogenesis of
lung fibrosis remains elusive and the lung epithelial cells
appear to be key producers of Fizz1, we generated trans-
genic mice which conditionally expresses Fizz1 under
the control of a doxycycline (Dox) inducible lung epithe-
lial cell specific promoter Scgb1a1 (Clara cell secretory
protein, CCSP). This promoter has been shown to lead
to transgene expression in the bronchial, bronchiolar
epithelium and to a lesser extent in alveolar epithelium[21,22]. This pattern of gene expression mimics the cel-
lular sites reported for Fizz1 expression in the lung
[7,18,19]. Transgenic mice constitutively expressing
Fizz1 in the pulmonary epithelium were used to deter-
mine effects on cellular influx in the lung, lung remodel-
ing, and experimental models of pulmonary fibrosis
using bleomycin or silica.
Methods
Generation of transgenic mice
Transgenic mice were generated by cloning full length
Fizz1 cDNA from mouse lung RNA and inserting into the
(TetO)7-CMV promoter. The (TetO)7-CMV Fizz1 trans-
gene consists of seven copies of tet operator DNA binding
sequence linked to a minimal CMV promoter, the mouse
Fizz1 cDNA, and SV40 polyadenylation signal. The con-
struct was injected into mouse oocytes generating (TetO)
7-CMV Fizz1
+/+ mice. All mice were derived from the
FVB/NJ inbred strain. Animals were housed under specific
pathogen-free conditions and handled in accordance with
protocols approved by the Institutional Animal Care and
Use Committee of the Children's Hospital Research Foun-
dation and the University of Cincinnati Medical Center.
Bitransgenic Fizz1 transgenic mice (abbreviated as CCSP/
Fizz1) were produced by mating Single transgenic Clara
Cell Specific Protein-rtTA+/− mice (abbreviated as CCSP/-
) with (TetO)7-CMV Fizz1
+/+ mice. To induce Fizz1 ex-
pression bitransgenic mice were administered doxycycline
(Dox) food (62.5 mg/kg). The fold increase in detectable
Fizz1 was determined by comparing pixels from the off
Dox and On Dox lanes in Figure 1 using a phosphorima-
ger and ImageQuant software [23].
PCR Genotyping
Transgenic mice were identified using PCR primers spe-
cific for each transgene as follows: 5' primer in the rat
CCSP promoter, 5' ACT GCC CAT TGC CCA AAC AC-
3'; 3' primer in rtTA coding sequence, 5'-AAA ATC TTG
CCA GCT TTC CCC-3'. Mice were identified for (TetO)
7-CMV Fizz1 transgene with PCR sense primer, 5' TGA
TGG TCC CAG TGA ATA CTG ATG-3'; anti-sense pri-
mer, 5' GGT CCA TGG TGA TAC AAG GGA CAT-3'.
Amplification of PCR products for CCSP and Fizz1 were
performed by denaturation at 94°C for 5 minutes and then
30 cycles of amplification at 94°C for 30 seconds, 57°C for
30 seconds and 72°C for 30 seconds, followed by 7 min-
utes extension at 72°C.
Western blot
Proteins in the total lung homogenates (50 μg) from the
CCSP/Fizz1 mice on Dox or off Dox for 2 weeks were
separated using SDS-PAGE and proteins transferred to
PVDF membrane as described earlier [23]. Fizz1 protein
was detected using a rabbit polyclonal anti-mouse Fizz1
Figure 1 Generation of CCSP/Fizz1 transgenic mice. (A) Gene targeting strategy for generating conditional CCSP/Fizz1 transgenic mice. TetO-
CMV Fizz1+/+ mice were generated by cloning full length Fizz1 cDNA from mouse lung RNA and inserting into the (TetO)7-CMV promoter. CCSP/
Fizz1 transgenic mice were produced by mating single transgenic CCSP/- mice with (TetO)7-CMV Fizz1
+/+ mice. To induce Fizz1 expression in
bitransgenic mice were administered doxycycline (Dox) as described in methods. (B) Western blot shows Fizz1 overexpression in the lungs of
CCSP/Fizz1 mice on Dox for two weeks. rFizz1 is a lane containing purified Fizz1 (Peprotech) loaded as a positive control. Lanes 1, 2 are duplicate
samples. The expressed Fizz1 in Dox treated transgenic mice migrated identically to the Fizz1 marker compared to CCSP/Fizz1 mice without Dox
treatment. The relative intensity of the bands in the On Dox lanes was increased about 14.1 fold.
Madala et al. Respiratory Research 2012, 13:51 Page 3 of 10
http://respiratory-research.com/content/13/1/51antibody (Peprotech, Rocky Hill, NJ, USA) and HRP-
conjugated anti-rabbit secondary antibody. Recombinant
Fizz1 protein was used as a positive control and signal
developed using a chemiluminescent kit.
Mouse model of bleomycin- and silica- induced fibrosis
Bleomycin-induced pulmonary fibrosis was performed as
described earlier with few modifications [24]. In brief,
CCSP/- and CCSP/Fizz1 mice were kept on Dox for two
weeks to establish Fizz1-induced changes in the lung. On
day 14, mice were anaesthetized with a xylazine and keta-
mine cocktail and given 0.15 U bleomycin sulfate (EMD)
in saline or saline alone via the I.T. route. On day 10 post
bleomycin, mice were sacrificed and the lungs were col-
lected for biochemical and histological analysis.
For silica-induced pulmonary fibrosis, mice on Dox
were anaesthetized with a xylazine and ketamine cocktail
and given 3 mg of 5 micron size sterile silica (US silica,
Beverly Springs, WV, USA) per mouse in 50 μl saline or
saline alone via the I.T. route. On day 28, mice were
sacrificed and the lungs were collected for biochemical
and histological analysis.
Lung histology and hydroxyproline measurements
Lungs were inflation fixed using 4% paraformaldehyde
and stained with hematoxylin and eosin (H&E) and mas-
son trichrome kit as described earlier [23].
Fibrosis in the lungs was quantified using a modified
assay for determination of hydroxyproline in tissues
[25]. In brief, the left lobe of lung was weighed and
hydrolyzed in 4 ml of 6 N HCl overnight at 110°C.
Hydrolyzed samples were neutralized with 1 N NAOH.
For colorization, chloramine-T (0.05 M) and the
aldehyde-perchloric acid reagent were added and sam-
ples placed in hot water bath at 60°C for 25 min. Thestandard hydroxyl-L-proline (EMD) solutions prepared
and treated identically to the samples to read at 550 nm
for samples and standards. Sample concentrations were
determined from the standard curve.
Quantification of broncho-alveolar lavage cells
Mice challenged with bleomycin or silica were eutha-
nized with sodium pentobarbital (65 mg/kg) and lungs
were lavaged sequentially with 0.7 and 0.5 ml aliquots of
PBS, pooled and used to determine total cell counts and
for cytospin preparations to determine macrophage cell
counts. Cells were isolated from the broncho-alveolar
lavage fluid (BALF) by centrifugation at 1250 rpm-5
minutes and the cell pellet resuspended in 1 ml of PBS
and cells were counted using hemocytometer.
FACS staining
Total lung cells were prepared for FACS staining by
mincing the lung in a complete RPMI medium and sub-
jected to collagenase digestion for 30 minutes at 37°C.
After digestion, lung cells were filtered through 100 μm
filter and counted by hemocytometer. About 1 million
cells were incubated with CD16/CD32 (Fc block) and
stained for surface antigens CD11b, CD11c, F4/80 and
CD45. Cell populations were analyzed using FACS Cali-
bur and Flow Jo as described earlier [26].
RNA preparation and real-time PCR
Total RNA was extracted from lung tissue using the
RNeasy Mini Kit from Qiagen (Qiagen Sciences, Valencia,
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All data was analyzed with Prism (Version 5; GraphPad).
Student t-test used to compare between two groups. One-
way ANOVA with Tukey`s Multiple Comparison post-test
is used to compare more than two experimental groups
and data were considered statistically significant for P
values less than 0.05.
Results
Generation of Fizz1 transgenic mice
Transgenic mice were generated by cloning full length
Fizz1 cDNA from mouse lung RNA and inserting into
the CMV-TetO promoter (TetO-Fizz1 mice). 4 different
lines were generated and screened for increases in Fizz1
transcripts. Selected TetO-Fizz1 mice were bred to
CCSP-rtTA activator mice to generate bitransgenic
CCSP-rtTA/tetO-Fizz1 mice (CCSP/Fizz1) conditionally
expressing epithelial Fizz1 protein when fed Dox con-
taining food (Figure 1A). To demonstrate the proper
translation and maturation of overexpressed Fizz1 tran-
scripts, CCSP/Fizz1 mice were administered Dox foodFigure 2 The lung epithelial specific Fizz1 overexpression increases th
were fed doxycycline food for 14 days. Total BAL cells increased with Fizz1 ov
unpaired student’s t test (n= 11/group). (B) CCSP/Fizz1 mice were fed doxycy
and anti-CD45 antibodies. Gating strategy and representation of CD45+ and C
CCSP/Fizz1 mice on no Dox. (C) Fizz1 overexpression has caused increase in t
significance is measured using unpaired student’s t test (n= 3/group). (D) CCS
were stained with anti-CD11c and anti-F4/80 antibodies. Gating strategy and
mice compared to CCSP/Fizz1 mice on no Dox. (E) Mice overexpressing Fizz1
do not stain for F4/80 consistent with changes in dendritic cells. Statistical sig
represent one of two independent experiments showing similar results.for 2 weeks and Fizz1 protein measured in lung homo-
genates by western blot. CCSP/Fizz1 mice on Dox
demonstrated about 14.1 fold increases in the signal in-
tensity at 9.5 kDa corresponding to a mature Fizz1 pro-
tein in lung homogenates over lung homogenates from
mice not treated with Dox (Figure 1B). Previous studies
demonstrate that target gene expression in bitransgenic
mice using the reverse tetracycline transactivator (rtTA)
expressed under the control of CCSP promoter is
restricted to alveolar Type II cells and non-ciliated bron-
chial and bronchiolar epithelial cells but not in ciliated
cells[27-29]. The highest-expressing line of founders was
subsequently used in all studies.
Effect of Fizz1 overexpression in the lungs
To assess the direct effects of Fizz1 overexpression,
CCSP/Fizz1 mice were fed Dox food for 14 days. CCSP/
Fizz1 mice on Dox demonstrated increased total cell
counts compared to mice without Dox (Figure 2A). There
were no differences between groups in cytospin differen-
tial with 99% macrophages recovered.e percentage of dendritic cells in the lung. (A) CCSP/Fizz1 mice
erexpression in CCSP/Fizz1 mice. Statistical significance is measured using
cline food for 14 days and total lung cells were stained with anti-CD11b
D11b+ cells in the lungs of Fizz1 overexpressing mice compared to
he percentage of CD45 and CD11b double positive cells. Statistical
P/Fizz1 mice were fed doxycycline food for 14 days and total lung cells
representation of DC, AM and IM in the lungs of Fizz1 overexpressing
demonstrate increases in the percentage of cells staining for CD 11c that
nificance is measured using unpaired student’s t test (n= 3/group). Data
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ment of bone marrow derived cells to the lung [30]. To as-
sess if epithelial overexpression of Fizz1 altered bone-
marrow-derived cell populations in the lung, total lung cells
from lung homogenates of CCSP/Fizz1 mice on and off
Dox were stained for markers of hematopoietic cells (CD45)
and monocytes/macrophages (CD11b). CCSP/Fizz1 mice
on Dox demonstrated increases in both the percentage and
total number of cells positive for both CD45 and CD11b
(Figure 2B and 2C). Total lung cells were also stained for
CD11c and F4/80, which are markers distinguishing den-
dritic cells from alveolar (AM) and interstitial macrophages
(IM) [31]. CCSP/Fizz1 mice on Dox demonstrated a more
than two fold increase in dendritic cells with no significant
changes in AM and IM (Figure 2D and 2E). Together, these
experiments show that overexpression of Fizz1 in the lung
resulted in an increased accumulation of bone-marrow-
derived dendritic cells, consistent with previous reports
[8,30]. We measured the transcripts for chemokines CCL3
and CCL19, which are known to be involved in the recruit-
ment of DCs to the lung. CCL3 and CCL19 transcript levels
are not changed in Fizz1 overexpressing mice compared to
control mice at day 5 on Dox (Additional file 1: Figure S1).
Therefore, mechanisms involved in the accumulation of
DCs in Fizz1 overexpressing mice could be direct, due to
Fizz1, or alternatively other unknown modulators could be
induced which would make the effects of Fizz1 indirect.
To assess the direct effects of Fizz1 overexpression on
lung remodeling, lung histology was assessed in CCSP/
Fizz1 mice at selected intervals up to 8 weeks of continuousFigure 3 The effect of Fizz1 overexpression on the lung histology. H&
8 weeks at 10X (top) & 20X (bottom) magnification. Histological examinatio
vessels and also inflammatory cells in the lung tissues of CCSP/- and CCSP/expression. There were no detectable changes in collagen
deposition, myofibroblasts accumulation or vascular re-
modeling between CCSP/Fizz1 mice on Dox compared to
controls (Figures 3). Together, these data suggest that Fizz1
increases the migration of bone-marrow derived cells to the
lung but has no direct effects on pulmonary remodeling in
normal mice without known inflammatory injuries.
Effect of Fizz1 overexpression on bleomycin-induced
inflammation and fibrosis
We next assessed if overexpression of lung epithelial Fizz1
altered the phenotype of inflammatory models of pulmon-
ary fibrosis. Fizz1 transcripts in wild type mice 10 days fol-
lowing bleomycin injury were increased more than 6-fold
from controls confirming activation of Fizz1 with bleo-
mycin injury (Figure 4A). CCSP/Fizz1 mice were fed Dox
food for 14 days to establish Fizz1-induced changes in the
lung cells. Mice were challenged with intratracheal bleo-
mycin on day 14 and continued on Dox for another
10 days before mice were euthanized (Figure 4B). CCSP/
Fizz1 mice on Dox receiving bleomycin had a greater loss
in body weight compared with CCSP/- control mice on
Dox and bleomycin (Figure 4C). Total BAL cells were
increased in both CCSP/Fizz1 and CCSP/- controls at
day10 post bleomycin challenge (Figure 4D). Compared
with saline treated controls there were no differences in
BAL cell differentials between bleomycin-challenged
groups (Figure 4E). Bleomycin-induced lung injury has
been shown to cause the recruitment of CD11b+ DCs
which may contribute to the fibrotic responses in the lungE stained lung sections from CCSP/- and CCSP/Fizz1 mice on Dox for
n reveals no detectable changes in the morphology of airways, blood
Fizz1 mice on Dox for 8 weeks.
Figure 4 Fizz1 overexpression in the lung has no effect on bleomycin-induced inflammation. (A) CCSP/- mice lungs were exposed to
saline or bleomycin via the I.T. route. Fizz1 transcripts were measured using RT-PCR at day10 post-bleomycin. Statistical significance is measured
using unpaired student’s t test (n = 5/group). (B) Schematic representation of Fizz1 induction by feeding doxycycline food and administration of
0.15U of bleomycin via the I.T. route. (C) CCSP/Fizz1 mice exposed to bleomcyin demonstrate accelerated weight loss compared with
CCSP/- controls receiving bleomycin. Data shown are mean± SEM (n = 7-8/group). (D) Total BALF cells quantified at day10 post bleomycin or
saline. Data shown are mean± SEM (n= 7-8/group). Statistical significance is measured using unpaired student’s t test. (E) Absolute counts of
macropahges in BALF cells were obtained from cell differentials. Data shown are mean± SEM (n = 7-8/group). Data represent one of two
independent experiments showing similar results.
Figure 5 Fizz1 overexpression has no effect on bleomycin-induced fibrosis in the lung. CCSP/- and CCSP/Fizz1 mice were exposed to
saline or bleomycin (0.15U) via the I.T. route, with pulmonary fibrosis assessed at day 10. (A) Masson Trichrome stained lung sections at 10X
magnification. Scale bar 200 μm. (B) Total lung weights were measured in all groups at day10 post-bleomycin. (C) The lung collagen deposition,
expressed as micromoles of hydroxyproline per lung. The above data is an average of two independent experiments with the total 7–14 mice
per group. Statistical significance is measured using one way ANOVA (n= 7-14/group).
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in the accumulation of CD45+CD11b+ cells in the lungs of
CCSP/- and CCSP/Fizz1 mice exposed to bleomycin com-
pared to saline treated CCSP/- mice (Additional file 1:
Figure S2). Fizz1 overexpression had no effect on the per-
centage of CD45+CD11b+ cells compared to CCSP/- mice
exposed to bleomycin. Masson trichrome staining did not
demonstrate differences in the degree or distribution of
matrix deposition in the lungs following bleomycin in the
CCSP/Fizz1 and CCSP/- mice challenged with bleomycin
(Figure 5A). Total lung weight and hydroxyproline levels
in the lungs were increased in the CCSP/Fizz1 and
CCSP/- mice following bleomycin, but there were no dif-
ferences between groups (Figure 5B and 5C). Together,
these data indicate Fizz1 overexpression resulted in
greater loss in body weight following bleomycin, but did
not alter the inflammatory cells or the total collagen con-
tent in the lung, suggesting that Fizz1 had no effect on
bleomycin-induced pulmonary fibrosis.Effect of Fizz1 overexpression on silica-induced
inflammation and fibrosis
Occupational exposure to crystalline silica has been shown
to form silicotic nodules characterized by localized inflam-
mation, fibroblast proliferation and excess collagen depos-
ition [33-35]. Resident and recruited macrophages have
been shown to play a pivotal role in developing silicotic
nodules, and increased proportions of Fizz1 expressingFigure 6 Fizz1 overexpression has no effect on silica-induced granulo
were exposed to saline or silica (3 mg/mice) via the I.T. route, pulmonary in
one of two independent experiments showing similar results with five anim
measured using one way ANNOVA (n= 5/group). (A) H&E stained lung sec
mice exposed to silica develop granulomatous nodules of similar size (B) T
counts of macrophages in BALF cells were obtained from cell differentials.macrophages are found in bronchoalveolar lavage specimens
from animals and humans with silica dust exposure [35-39].
To determine whether Fizz1 overexpression altered silica-
induced pulmonary inflammation and fibrosis, CCSP/Fizz1
were fed Dox food then challenged with intratracheal silica
and continued on Dox for another 28 days following silica
instillation. CCSP/Fizz1 and CCSP/- control mice on Dox
developed granulomatous nodules largely comprising of
macrophages but there were no differences in the numbers
or distribution of nodules within groups (Figure 6A). Total
BAL cells were increased in both CCSP/Fizz1 and CCSP/-
controls but there were no differences between groups and
no differences in cell differential (Figure 6B). Total macro-
phage numbers in BAL were increased in CCSP/Fizz1 mice
compared to CCSP/- mice exposed to silica (Figure 6C).
Mason’s trichrome staining did not demonstrate differences
in the degree or distribution of matrix deposition in the
lungs following silica in either group (Figure 7A). Total lung
weight and hydroxyproline levels in the lungs were increased
in the CCSP/Fizz1 and CCSP/- controls following silica, but
there were no differences between groups (Figure 7B and
7C). Together, these data indicate that Fizz1 overexpression
did not alter inflammation or the total collagen content in
the lungs of silica-exposed mice.Discussion
The current study demonstrates that constitutive over-
expression of Fizz1 in lung epithelial cells increases thematous inflammation in the lung. CCSP/- and CCSP/Fizz1 mice
flammation assessed on day 28 after silica instillation. Data represent
als per group. Data shown are mean± SEM. Statistical significance is
tions at 10X magnification. Scale bar 200 μm. CCSP/- and CCSP/Fizz1
otal BAL cells counted at day 28 post silica or saline. (C) Absolute
Figure 7 Fizz1 overexpression has no effect on silica-induced fibrosis in the lung. CCSP/- and CCSP/Fizz1 mice were exposed to saline or
silica (3 mg/mice) via the I.T. route, with pulmonary fibrosis assessed on day 28 after silica instillation. One of two independent experiments is shown
with five animals per group. Data shown are mean±SEM. Statistical significance is measured using one way ANOVA . (A) Masson Trichrome stained
lung sections at 10X magnification. CCSP/- and CCSP/Fizz1 mice exposed to silica develop granulomatous nodules of similar size. Scale bar 200 μm. (B)
Total lung weights were measured in all groups at day 28 post-silica. CCSP/- and CCSP/Fizz1 mice exposed to silica showed increases in the lung
weights and no difference with Fizz1 overexpression. (C) The lung collagen deposition, expressed as micromoles of hydroxyproline per lung.
CCSP/- and CCSP/Fizz1 mice exposed to silica showed increases in the lung weights and no difference with Fizz1 overexpression.
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in the lung. Our findings support earlier work where
Fizz1 was overexpressed in the lung using a recombinant
adeno-associated viral (AAV) vector, and bone marrow
derived cells of hematopoietic lineage were recruited to
the smooth muscle layer of pulmonary vessels [30]. In
the current study we further characterized the changes
in the lung cell population with Fizz1 overexpression
using FACS analysis and demonstrated that Fizz1
induced recruitment was associated with a higher per-
centage of cells staining for both CD11c and F4/80,
which are markers associated with dendritic cells. This is
the first study to demonstrate a direct role for Fizz1 pro-
duced in lung epithelial cells in vivo in the recruitment
of dendritic cells into the lung and further supports a
role for the Fizz family as a chemoattractant for bone
marrow derived cells. Recently, Fizz2 has also been
shown to directly cause chemoattraction of bone-
marrow-derived dendritic cells, and lung recruitment of
bone-marrow-derived cells including dendritic cells was
impaired in Fizz2 knockout mice [40].
Our study demonstrated that epithelial overexpres-
sion of Fizz1 without a concomitant lung injury was
not associated with changes in lung architecture or
lung fibrosis. The role of Fizz1 in vivo in altering pul-
monary fibrosis is unclear. Fizz1 overexpression with
adenoviral vectors increased thickening and collagen
surrounding pulmonary arteries [30]. However, Fizz1knockout mice challenged with the parasitic eggs of S.
Mansoni eggs displayed heightened pulmonary fibrosis
suggesting that Fizz1 is a negative regulator of parasite
induced pro-fibrotic Th2 cytokines and in this model
Fizz1 is anti-fibrotic [7]. Another recent study using
Fizz1 KO mice demonstrates that Fizz1 was largely dis-
pensable during Aspergilus fumigatous allergen-induced
production of Th2 cytokines, eosinophilia and airway
remodeling [19].
The migration of myeloid cells from the bone marrow
to the lung has been shown to regulate inflammation
and the pathogen burden in the lung. Data over the past
decades also supports a role for bone marrow derived
fibrocytes in contributing to the cellular accumulation of
mesenchymal cells and extracellular matrix [41]. Al-
though, myeloid cells have been shown to migrate into
the lung, the secretory mediators involved in the migra-
tion and maturation to different cell subsets, along with
their functional role remains an area of active investiga-
tion. The present study does not establish whether Fizz1
chemoattraction of dendritic cells is due to Fizz1 alone
or Fizz1 regulation or interaction with other chemo-
attractant molecules. The myeloid cell subsets that
populate in the lung include dendritic cells, alveolar
macrophages and interstitial macrophages. Notably,
findings of this study demonstrate that Fizz1 overexpres-
sion increased dendritic cells in the lung without altering
lung architecture. Dendritic cells are critical members of
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cessing and mediating immunity responses. Lung den-
dritic cells have been shown to accumulate in human
fibrotic lung disease and bleomycin-induced fibrosis, but
have not been shown to independently and directly
cause lung remodeling. The present study shows that
Fizz1 mediated attraction of dendritic cells was not ad-
equate to influence lung fibrosis. Fizz1 overexpression
has no effect on CD45 +CD11b + cells in the lung during
bleomycin-induced injury. Future studies are warranted
to identify the roles of Fizz1-recruited dendritic cells in
immunity against bacterial and viral pathogens and also
infections associated injury and remodeling in the lung.
As we were not able to demonstrate direct remodeling
from Fizz1 overexpression, we examined if Fizz1 overex-
pression altered fibrosis in known inflammatory models.
Fizz1 was overexpressed in the lung prior to challenge
with bleomycin or silica. Both models induce inflamma-
tory changes leading to fibrosis; however the inflamma-
tory responses are different with bleomycin resulting in
an oxidative injury associated with neutrophil influx,
while silica leads to macrophage-related activation and
formation of inflammatory nodules. With both chal-
lenges, overexpression of Fizz1 did not alter the degree
of lung remodeling. In the bleomycin injury, expression
of Fizz1 did cause a greater loss of body weight. Al-
though the mode of action is not known, these data fur-
ther support the concept that lung epithelial cell
produced Fizz1 has systemic effects consistent with ef-
fect on systemic recruitment of bone marrow derived
cells. While the precise mode of activity is not known,
Fizz1 has been shown to alter IL-13 induced chemokine
levels, inhibit nerve growth factor neuronal survival, and
cause bone marrow cell migration in a transwell assay
through interactions with Bruton’s tyrosine kinase[42].
Thus Fizz1 may act directly or indirectly by influences
on cytokine or growth factor induced regulation.
In spite of an increase in Fizz1 transcripts induced by
bleomycin in the lung, the results of our study do not
support a role for Fizz1 produced in the lung epithelium
as a direct cause of lung fibrosis. In the present study,
single instillations of bleomycin and silica were used
which cause a slowly resolving inflammation leading to
diffused fibrosis or nodular fibrosis. In hypoxic injury,
the injury is continuous and leads to pulmonary hyper-
tension. Fizz1 may act in a localized fashion to increase
fibrotic responses around pulmonary arterioles during
chronic hypoxia but not to increase granuloma forma-
tion around S. mansoni parasites or retained silica parti-
cles. In addition, the differences in the activation of
immune pathways, cellular sites of Fizz1 production
such as macrophages and eosinophils, and the amount
of Fizz1 produced may be responsible for observed dif-
ferences between studies. Lack of observable histologicaland hydroxyproline differences in bleomycin or silica-
induced lung remodeling in Fizz1 overexpressing mice
could be due to doses of bleomycin or silica. While the
doses used in this study have been used in previous
studies, the tested dose may mask or not be a sufficient
dose to show Fizz1 effects. Alternatively, other members
of the Fizz family may be involved in pulmonary fibrosis.
When challenged with bleomycin, Fizz2 knockout mice
show a decrease in the absolute number of total BAL
cells, cytokine gene expression and extracellular matrix
deposition than control mice [40].
Conclusions
The findings in the current study indicated that epithe-
lial overexpression of Fizz1 promoted the recruitment of
bone marrow-derived dendritic cells into the lung, but
did not directly induce fibrosis or alter inflammatory
models of fibrosis.
Additional file
Additional file 1: Figure S1. Fizz1 overexpression has no significant
effect on CCL3 and CCL19 transcripts in the lung. CCSP/Fizz1 mice were
fed with or without DOX for 5 days and transcripts for CCL3 and CCL19
were measured in the total lung transcripts using Real Time PCR. Figure
S2. Fizz1 overexpression has no effect on bleomycin-induced increases in
CD45 +CD11b + cells in the lung. Total lung cells were stained with anti-
CD11b and anti-CD45 antibodies at day10 post bleomycin or saline.
Gating strategy of CD45 + CD11b + cells in the lungs of bleomycin
exposed and Fizz1 overexpressing mice compared to CCSP/- mice
exposed to bleomycin or saline. Bleomycin treatment has increased the
percentage of CD45 +CD11b + cells. Fizz1 overexpression had no
modifying effects on bleomycin-induced increase in the percentage of
CD45 +CD11b + cells.
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